South Korea Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

South Korea Drug Delivery Devices Market Analysis

The South Korea drug delivery devices market stands at USD 5.08 billion in 2025 and is forecast to reach USD 7.63 billion by 2030, advancing at an 8.47% CAGR. Rising life expectancy, rapid urbanization, and strong domestic production underpin this growth. A national policy focus on chronic disease management, coupled with high digital‐health adoption, is accelerating uptake of connected pumps, smart inhalers, and other patient-centric technologies. Government fast-track approvals for breakthrough devices shorten launch timelines, while a broad biologic pipeline pushes demand for advanced injectable platforms. Competitive intensity is increasing as domestic innovators align with global leaders to commercialize novel formats across oncology, diabetes, and pain care.

South Korea Drug Delivery Devices Market Trends and Insights

Ageing Population Coupled with High Chronic Disease Burden

More than 20% of citizens will be 65 or older by end-2025, and 54.8% of these older adults manage multiple chronic conditions.Complex medication schedules heighten demand for user-friendly devices that deliver several drugs with minimal disruption. Frequent comorbid clusters, such as cardiometabolic and arthritis, are steering suppliers toward combination systems tailored to specific patient groups. Out-of-pocket costs nearly triple for multimorbid individuals, motivating insurers to endorse efficient delivery tools that improve adherence and lower total care expenditure.

Technological Advancement and Supportive Government Policies

National programs like the High-Tech Bio Initiative and the 1st Master Plan for Fostering and Supporting the Medical Device Industry provide funding, testbeds, and accelerated reviews that shorten commercialization cycles. Reforms at the Ministry of Food and Drug Safety (MFDS) carve dedicated pathways for breakthrough devices, shrinking approval windows and encouraging early market entry.[3] Nanotechnology-enabled carriers, now progressing through clinical pipelines, demonstrate improved drug loading and targeted release, reinforcing South Korea’s ambition to lead AI-integrated, patient-centric healthcare.

Stringent Approval and Vigilance Delaying Novel Device Launches

MFDS classifies devices by risk, and Classes II–IV undergo extensive dossier reviews, including quality, safety, and sometimes clinical data. For foreign firms, the mandatory Korean License Holder adds administrative layers. Post-market surveillance lists track 52 device categories, imposing ongoing reporting that can deter small entrants.

Other drivers and restraints analyzed in the detailed report include:

1. High Digital Health Adoption Supporting Smart Pumps & Connected Inhalers
2. Expanding Domestic Biosimilar & Biologic Pipeline Requiring Injectable Formats
3. Risks and Safety Concerns Related to Devices

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Injectable platforms account for 36.78% of South Korea drug delivery devices market share in 2024, reflecting their versatility across diabetes, oncology, and autoimmune therapy. Demand remains steady as biologics dominate development pipelines. Implantable systems, posting a 10.46% CAGR to 2030, benefit from biocompatible polymers that release drugs over months, lowering dosing frequency for chronic pain and hormone disorders. Clinical data from domestic cohorts confirm reduced opioid exposure when intrathecal pumps replace systemic analgesics.

Wearable injectors, fixed‐dose autoinjectors, and on-body pumps enhance self-management. Transdermal patches broaden options for neurological and pain conditions, with twice-weekly rivastigmine patches easing caregiver workloads. Inhalers, now integrating dose-tracking chips, link to mobile apps for personalized coaching. Nasal and ocular inserts remain niche but attract R&D interest for CNS drugs and ophthalmic biologics. Growing acceptance of these alternatives signals ongoing diversification within the South Korea drug delivery devices market.

Injectables cover 56.53% of administration routes in 2024, favored for their proven bioavailability and compatibility with complex molecules. Oral mucosal formats show the fastest 10.68% CAGR, drawing traction for rapid onset and ease of use. Thin films dissolving in seconds avoid first-pass metabolism, helping dysphagic patients adhere to regimens. The South Korea drug delivery devices market size for mucosal routes is projected to expand steadily alongside R&D investments that improve permeability enhancers and taste-masking agents.

Transdermal technology advances through micro‐needle arrays that painlessly breach the stratum corneum and deliver steady plasma levels over several days. Respiratory applications hold a stable share as chronic obstructive pulmonary disease and asthma prevalence rises. Ocular and nasal routes gain strategic importance for vaccines and neuro-active peptides that target the brain, bypassing systemic clearance barriers.

The South Korea Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Transdermal, Ocular, and More), Application (Diabetes, Oncology, Cardiovascular Disorders and More), and End Users (Hospitals, Ambulatory Surgical Centres, and More). The Market and Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Baxter
2. Bayer
3. Roche
4. EOFlow Co., Ltd
5. Johnson & Johnson
6. Novartis
7. TDS Pharm
8. QuadMedicine Co., Ltd.
9. Daewon Pharmaceutical Co., Ltd.
10. Dongkook Pharmaceutical Co., Ltd.
11. Yuhan Corporation
12. Sanofi
13. Beckton Dickinson
14. Ypsomed
15. Medtronic
16. Terumo
17. Teva Pharmaceutical Industries
18. LG Chem
19. Icure Pharmaceutical Inc

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support